ICER push­es back on FDA's po­ten­tial con­ver­sion of Sarep­ta's gene ther­a­py to full ap­proval

The in­tegri­ty of the FDA’s ac­cel­er­at­ed ap­proval process should be called in­to ques­tion if the agency grants full ap­proval to treat­ments that have failed their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER